Vijay Singh
Cupid Limited, (BSE – 530843, NSE – CUPID), a diversified Indian healthcare and consumer products company with a growing focus on in-vitro diagnostics (IVD),wellness, and personal care, announced that it has received CE (EU IVDR) Certification for two in-vitro diagnostic (IVD) products – the CupiKIT HIV 1&2 Antibody Test Kit and the CupiKITHepatitis B Surface Antigen (HBsAg) Test Kit.
The certifications have been granted under the European Union In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR), among the most stringent regulatory standards globally. These approvals enable Cupid Limited to market the certified products across the European Economic Area (EEA) and other CE-recognized international markets.
The approvals mark a key milestone in Cupid’s strategy to build a globally compliant and diversified rapid diagnostics portfolio. The addition of HIV 1&2 and Hepatitis B test kits strengthens the Company’s footprint in infectious disease diagnostics, complementing its existing focus on maternal health and screening solutions.
The newly certified products are intended for early detection and large-scale screening programs, particularly across public health initiatives and institutional procurement channels in Europe, Africa, and other emerging markets. The certifications also enhance Cupid’s eligibility to participate in government tenders, multilateral agency programs, and regulated international healthcare supply chains where EU IVDR compliance is mandatory.
These certifications further reinforce Cupid Limited’s transition into a broader, innovation-led healthcare and diagnostics platform and position the Company to capitalize on rising global demand for accurate, affordable, and rapid diagnostic solutions.
Commenting on the development, Mr. Aditya Kumar Halwasiya, Chairman & Managing Director of Cupid Limited, said “The CE (EU IVDR) certification for our HIV 1&2 and Hepatitis B test kits is a meaningful step in strengthening our global diagnostics business. These approvals expand our access to regulated international markets and enhance our ability to participate in large-scale screening and public health programs. We continue to focus on building a reliable and affordable diagnostics portfolio while scaling our presence across key global regions to address growing healthcare needs.”
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
